Nouvelle déclaration d'incident
No de la demande: 2020-0462
Numéro de référence du titulaire d'homologation: 2019-US-028016
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: FLORIDA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-139
Nom du produit: Hartz UltraGuard Pro Flea and Tick Collar
Autre (préciser)
CollarOui
Inconnu
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Homme
3
15
lbs
Cutanée
>24 hrs <=3 days / >24 h <=3 jours
>24 hrs <=3 days / >24 h <=3 jours
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 13-Oct-2019 the pet owner applied one Hartz UltraGuard Pro Flea and Tick collar (tetrachlorvinphos, s-methoprene) to the cat. On 16-Oct-2019 the cat suddenly collapsed and died. The product was applied to two other cats in the home that remained asymptomatic. Though the pet owner was interested in pursuing a necropsy it is unknown if one was completed. No further information was received in this case.
Mort
Assessment: This product is considered to have a wide margin of safety in cats. If a small amount of product was ingested, only minor oral irritation or gastrointestinal upset resulting in drooling of vomiting would be expected. Sudden onset of collapse and death are not expected and not likely due to product use. Other causes including unknown trauma, underlying cardiac disease and aortic thromboembolism (saddle thrombus) should be considered. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.